Small cell lung cancer

Where do we go from here?

Lauren Averett Byers, Charles M. Rudin

Research output: Contribution to journalArticle

Abstract

Small cell lung cancer (SCLC) is an aggressive disease that accounts for approximately 14% of all lung cancers. In the United States, approximately 31,000 patients are diagnosed annually with SCLC. Despite numerous clinical trials, including at least 40 phase 3 trials since the 1970s, systemic treatment for patients with SCLC has not changed significantly in the past several decades. Consequently, the 5-year survival rate remains low at <7% overall, and most patients survive for only 1 year or less after diagnosis. Unlike nonsmall cell lung cancer (NSCLC), in which major advances have been made using targeted therapies, there are still no approved targeted drugs for SCLC. Significant barriers to progress in SCLC include 1) a lack of early detection modalities, 2) limited tumor tissue for translational research (eg, molecular profiling of DNA, RNA, and/or protein alterations) because of small diagnostic biopsies and the rare use of surgical resection in standard treatment, and 3) rapid disease progression with poor understanding of the mechanisms contributing to therapeutic resistance. In this report, the authors review the current state of SCLC treatment, recent advances in current understanding of the underlying disease biology, and opportunities to advance translational research and therapeutic approaches for patients with SCLC.

Original languageEnglish (US)
Pages (from-to)664-672
Number of pages9
JournalCancer
Volume121
Issue number5
DOIs
StatePublished - Mar 1 2015

Fingerprint

Small Cell Lung Carcinoma
Translational Medical Research
Therapeutics
DNA Fingerprinting
Non-Small Cell Lung Carcinoma
Disease Progression
Lung Neoplasms
Survival Rate
Clinical Trials
RNA
Biopsy
Pharmaceutical Preparations
Neoplasms
Proteins

Keywords

  • Genomics
  • Novel therapies
  • Proteomics
  • Small cell lung cancer
  • Translational research

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Small cell lung cancer : Where do we go from here? / Byers, Lauren Averett; Rudin, Charles M.

In: Cancer, Vol. 121, No. 5, 01.03.2015, p. 664-672.

Research output: Contribution to journalArticle

Byers, LA & Rudin, CM 2015, 'Small cell lung cancer: Where do we go from here?', Cancer, vol. 121, no. 5, pp. 664-672. https://doi.org/10.1002/cncr.29098
Byers, Lauren Averett ; Rudin, Charles M. / Small cell lung cancer : Where do we go from here?. In: Cancer. 2015 ; Vol. 121, No. 5. pp. 664-672.
@article{fc5fcfd25de94d0582d9b973a21b0fdc,
title = "Small cell lung cancer: Where do we go from here?",
abstract = "Small cell lung cancer (SCLC) is an aggressive disease that accounts for approximately 14{\%} of all lung cancers. In the United States, approximately 31,000 patients are diagnosed annually with SCLC. Despite numerous clinical trials, including at least 40 phase 3 trials since the 1970s, systemic treatment for patients with SCLC has not changed significantly in the past several decades. Consequently, the 5-year survival rate remains low at <7{\%} overall, and most patients survive for only 1 year or less after diagnosis. Unlike nonsmall cell lung cancer (NSCLC), in which major advances have been made using targeted therapies, there are still no approved targeted drugs for SCLC. Significant barriers to progress in SCLC include 1) a lack of early detection modalities, 2) limited tumor tissue for translational research (eg, molecular profiling of DNA, RNA, and/or protein alterations) because of small diagnostic biopsies and the rare use of surgical resection in standard treatment, and 3) rapid disease progression with poor understanding of the mechanisms contributing to therapeutic resistance. In this report, the authors review the current state of SCLC treatment, recent advances in current understanding of the underlying disease biology, and opportunities to advance translational research and therapeutic approaches for patients with SCLC.",
keywords = "Genomics, Novel therapies, Proteomics, Small cell lung cancer, Translational research",
author = "Byers, {Lauren Averett} and Rudin, {Charles M.}",
year = "2015",
month = "3",
day = "1",
doi = "10.1002/cncr.29098",
language = "English (US)",
volume = "121",
pages = "664--672",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "5",

}

TY - JOUR

T1 - Small cell lung cancer

T2 - Where do we go from here?

AU - Byers, Lauren Averett

AU - Rudin, Charles M.

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Small cell lung cancer (SCLC) is an aggressive disease that accounts for approximately 14% of all lung cancers. In the United States, approximately 31,000 patients are diagnosed annually with SCLC. Despite numerous clinical trials, including at least 40 phase 3 trials since the 1970s, systemic treatment for patients with SCLC has not changed significantly in the past several decades. Consequently, the 5-year survival rate remains low at <7% overall, and most patients survive for only 1 year or less after diagnosis. Unlike nonsmall cell lung cancer (NSCLC), in which major advances have been made using targeted therapies, there are still no approved targeted drugs for SCLC. Significant barriers to progress in SCLC include 1) a lack of early detection modalities, 2) limited tumor tissue for translational research (eg, molecular profiling of DNA, RNA, and/or protein alterations) because of small diagnostic biopsies and the rare use of surgical resection in standard treatment, and 3) rapid disease progression with poor understanding of the mechanisms contributing to therapeutic resistance. In this report, the authors review the current state of SCLC treatment, recent advances in current understanding of the underlying disease biology, and opportunities to advance translational research and therapeutic approaches for patients with SCLC.

AB - Small cell lung cancer (SCLC) is an aggressive disease that accounts for approximately 14% of all lung cancers. In the United States, approximately 31,000 patients are diagnosed annually with SCLC. Despite numerous clinical trials, including at least 40 phase 3 trials since the 1970s, systemic treatment for patients with SCLC has not changed significantly in the past several decades. Consequently, the 5-year survival rate remains low at <7% overall, and most patients survive for only 1 year or less after diagnosis. Unlike nonsmall cell lung cancer (NSCLC), in which major advances have been made using targeted therapies, there are still no approved targeted drugs for SCLC. Significant barriers to progress in SCLC include 1) a lack of early detection modalities, 2) limited tumor tissue for translational research (eg, molecular profiling of DNA, RNA, and/or protein alterations) because of small diagnostic biopsies and the rare use of surgical resection in standard treatment, and 3) rapid disease progression with poor understanding of the mechanisms contributing to therapeutic resistance. In this report, the authors review the current state of SCLC treatment, recent advances in current understanding of the underlying disease biology, and opportunities to advance translational research and therapeutic approaches for patients with SCLC.

KW - Genomics

KW - Novel therapies

KW - Proteomics

KW - Small cell lung cancer

KW - Translational research

UR - http://www.scopus.com/inward/record.url?scp=84923307798&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923307798&partnerID=8YFLogxK

U2 - 10.1002/cncr.29098

DO - 10.1002/cncr.29098

M3 - Article

VL - 121

SP - 664

EP - 672

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 5

ER -